



65 West Watkins Mill Road  
Gaithersburg, MD 20878  
tel: 240-632-0740  
fax: 240-632-0735  
[www.genvec.com](http://www.genvec.com)

**FOR IMMEDIATE RELEASE:**

**CONTACT:**  
**Douglas J. Swirsky**  
**Chief Financial Officer**  
**(240) 632-5510**  
[dswirsky@genvec.com](mailto:dswirsky@genvec.com)

## **GENVEC ANNOUNCES THIRD QUARTER 2007 RESULTS CONFERENCE CALL**

**GAITHERSBURG, MD** – October 31, 2007 – GenVec, Inc. (Nasdaq:GNVC) will release its third quarter 2007 financial results on Wednesday, November 7, 2007 before the opening of the U.S. financial markets. The company will also host a conference call with a live internet broadcast that will provide a business update and review of its third quarter results on the same day at 4:30 p.m. ET (1:30 p.m. PT).

To participate in the live conference call, please dial 888.679.8040 (U.S. or Canada) or 617.213.4851 (international) and use access code 18451124. Participants may pre-register for the call anytime at: <https://www.theconferencingservice.com/prereg/key.process?key=PGCVXRTKE>. Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 6:30 p.m. on November 7, 2007 through November 14, 2007. To listen to the audio replay, dial 888.286.8010 (U.S. or Canada) or 617.801.6888 (international) and use access code 14472963.

A live webcast of the conference call will be available in listen only mode on the Company's web site at [www.genvec.com](http://www.genvec.com) and archived for 30 days. To access the webcast or the replay, go to the "Investor Relations" page and click on the link to the Webcasts and Data section.

### ***About GenVec***

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™ is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at [www.genvec.com](http://www.genvec.com) and in the Company's various filings with the Securities and Exchange Commission.

###